Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. has demonstrated significant advancements in the delivery of biologics through its RaniPill platform, with compelling data showing that RT-114 delivers PG-102 via oral administration with enhanced bioavailability compared to subcutaneous dosing. The company's collaboration with Chugai provides validation from a prominent industry player and positions Rani to leverage a multi-billion dollar market for next-generation oral drugs, particularly in the obesity therapy sector. Additionally, Rani's strong financial standing, with a cash runway extending through 2028, enables it to invest strategically in advancing its RT-114 program, which could unlock substantial value for shareholders as the company endeavors to improve patient adherence through oral dosing.

Bears say

The analysis of Rani Therapeutics Holdings Inc. indicates that the company faces significant challenges impacting its financial outlook. Concerns over competition disrupting the pipeline and potential underperformance in product sales jeopardize revenue projections, especially if reimbursement levels do not align with current forecasts. Additionally, while the safety profile of the RaniPill platform is viewed positively, the reliance on achieving FDA approval and the risk of failure in future clinical trials contribute to a cautious stance on the stock's value.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.